RMD — ResMed Inc.

Is RMD overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Overbought As of August 19, 2026

ResMed Inc. (RMD) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $219.98. The rating moved from Neutral to Overbought on August 18, 2026.

See all overbought Healthcare stocks →

AI analysis

ResMed Inc. (RMD) combines a durable devices business with growing software and cloud-enabled care management, producing predictable recurring revenue and strong free cash flow. Competitive advantages include market leadership in sleep and chronic respiratory care, a global distribution footprint, and expanding subscription monetization that can lift margins and stickiness. Near-term sentiment is constructive, which may support modest multiple expansion, while longer-term growth depends on continued adoption of remote-monitoring services, product refresh cycles, and incremental software/analytics monetization. Primary concerns are payer reimbursement trends, regulatory pressure on digital-health data practices, and competitive pricing dynamics. Overall outlook is constructive but warrants monitoring of reimbursement developments, regulatory actions, and execution on software monetization initiatives.

Key factors

  • Recurring revenue from durable medical equipment and high-margin consumables (masks, disposables) supporting predictable cash flow
  • Market leadership in sleep-disordered breathing and growing share in home ventilation and chronic respiratory care
  • Increasing attach rates for cloud-connected devices and subscription-based software/remote-monitoring services that drive higher lifetime value
  • Favorable long-term demographic tailwinds (aging populations, rising diagnosis rates of sleep apnea)
  • Resilient margins and strong free cash flow enabling R&D, tuck-in M&A, and shareholder returns
  • Near-term constructive market sentiment (risk-on rotation) could support multiple expansion for growth-oriented healthcare names
  • Operational flexibility and global distribution network that mitigate single-market exposure

Risks

  • Reimbursement pressure and payer strategic rationalization that could reduce device and consumable volumes or pricing
  • Regulatory and compliance risk for digital-health and telehealth services (privacy/FTC enforcement) increasing compliance costs and limiting certain growth channels
  • Competitive pressure from large device players and lower-cost entrants (e.g., Philips, Fisher & Paykel) on hardware and consumables
  • Macroeconomic weakness or reductions in elective care budgets that slow equipment upgrades and new patient flow
  • Foreign exchange and supply‑chain disruption risks affecting margins and delivery timelines
  • Geopolitical headlines or unexpected adverse regulatory actions that could create short-term share volatility

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for RMD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.